Lotte Bjerre Knudsen (45:38): Yeah, there is another hormone that's also in phase three clinical development, right
Key Takeaways Starting dose: 2 mg once weekly for 4 weeks Titration pace: Increase every 4 weeks: 2 4 8 12 mg Maximum dose: 12 mg weekly (Phase 2/3 clinical trial protocol) Total ramp-up: ~16 weeks to reach maximum dose Mechanism: Triple agonist (GLP-1 + GIP + Glucagon), the only triple-agonist in late-stage trials Weight loss: Up to 24.2% at 48 weeks (Phase 2) and 28.7% at 68 weeks (Phase 3 TRIUMPH-4) GLP-3 Retatrutide Dosage Chart Free printable reference chart showing the retatrutide (GLP-3) clinical trial titration schedule from 2 mg to 12 mg weekly
With GLP-1 medications and the personalized care provided by Set Point, youll have a strong ally in your journey toward improved well-being and weight management
The downside is that the population may not be representative of the overall population since it is made of veterans (for example, 95% male)
BUILDING FROM A STRONG PLATFORM For an autoinjector to function safely and effectively in patients hands, multiple critical design factors must be considered during development
It can also develop on other parts of the body, including the face and the nose, so its sometimes mistaken for rosacea